Volume 25, Number 1—January 2019
Dispatch
Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States
Table 1
Demographic information for study of parechovirus A3 neutralizing antibodies, Australia, the Netherlands, and United States*
Sample group |
Institute |
Sample type |
No. (%) patients |
Patient age, y |
|
Mean |
SD |
||||
Country (state) and years | |||||
NL 2006–2007 | RIVM | P | 140 (11) | 27.8 | 21.9 |
NL 2015–2016 | AMC | R, S | 140 (11) | 27.8 | 21.5 |
USA (MO) 2012–2013 | CMH | R | 120 (9) | 30.8 | 18.3 |
USA (MO) 2017 | CMH, TMC | R | 171 (13) | 25.5 | 18.8 |
AUS (VIC) 2011–2012 | VIDRL | R | 138 (11) | 26.5 | 19.9 |
AUS (VIC) 2015–2016 | VIDRL | R | 138 (11) | 26.4 | 19.6 |
AUS (NSW) 2011–2012 | WH, POW | R | 185 (14) | 26.1 | 23.2 |
AUS (NSW) 2015–2016 |
WH, POW |
R |
257 (20) |
23.9 |
20.6 |
Sex† | |||||
M | 598 (46) | 25.7 | 21.3 | ||
F |
580 (45) |
25.5 |
20.5 |
||
Age, y | |||||
<1 | 148 (11) | 0.4 | 0.3 | ||
1–2 | 52 (4) | 1.8 | 0.6 | ||
3–4 | 41 (3) | 3.8 | 0.6 | ||
5–9 | 120 (9) | 7.2 | 1.5 | ||
10–19 | 220 (17) | 15.8 | 2.7 | ||
20–29 | 184 (14) | 24.8 | 2.9 | ||
30–39 | 172 (13) | 34.2 | 2.8 | ||
40–49 | 162 (13) | 44.6 | 2.8 | ||
50–59 | 89 (7) | 54.8 | 3.2 | ||
60–69 | 62 (5) | 64.3 | 2.8 | ||
>69 |
38 (3) |
76.4 |
5.3 |
||
Total | 1,288 |
*AMC, Academic Medical Center; AUS, Australia; CMH, Children’s Mercy Hospital; NL, the Netherlands; P, population-based sampling; POW, Prince of Wales Hospital; R, residual serum from hospitalized patients and community; RIVM, National Institute for Public Health and the Environment; S, AMC staff; SD, standard deviation; TMC, Truman Medical Center; VIC, Victoria; NSW, New South Wales; VIDRL, Victorian Infectious Diseases Reference Laboratory; WH, Westmead Hospital.
†Information on sex not available for US 2017 adult samples.